Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This should be sufficient to extend Keytruda's patent life which is Mercks goal.
What's sauce for the goose is sauce for the gander. Hence, I always take a gander at your posts
How many years of data on spoofing do they claim to have?
Didn't DI say they wouldn't pr applications/submissions?
My question also. Today was supposed to be an important date re: the lawsuit but the great MIA news is dominating the discussion.
Citadel plans to make enough off the stock price increase to offset the cost of the settlement which will be announced Monday!
Lol. Just kidding
Looks like we're going it alone, hopefully with some partnerships.
Let's say spoofing caused an 80% decline. I mean, as long as we're making up numbers to support a hypothetical why not pick numbers that support our theory?
If EW was going to step in why did nwbo need to obtain financing from Streeter Capital?
Bloodbath today
All companies with exposure to the bank are required to report it nlt Wednesday. Since nwbo is subject to misinformation here and elsewhere they got out ahead of fudsters before Monday's open. Said fudsters are left to bemoan the uselessness of such a pr since they're now left with nothing better to do.
It was reported today that billions in deposits were moved ahead of the shutdown today. The smart money took their money and ran.
Biden's budget is DOA but the money for a cancer moonshot program should survive the budget process. In any case, it's next year's budget so the money won't be available any time soon.
Mgt made the decision to prioritize approval in the UK for a reason.
Citadel took a little hit today. They have a 5 5% stake in Silvergate capital which announced today that its folding. 25 million loss for Citadel.
Just reacting to Fifes rep on my part. Hope you're right
Fife has a bad rep as a toxic lender. A deep dive into the terms of the loan is called for. Unfortunately I'm not knowledgeable enough. Maybe someone here is.
I believe streeterville capital is owned by Fife. If so this isn't good news at all. In fact I would call it evidence of desperation.
The irony is thick isn't it
If that's true then the ask should be way north of 100 million.
Since it's a contingency deal nwbo's share will be somewhat less than 100 million if that's the settlement amount. So when you're discussing the amount I'd expect it to be about half or so that goes to nwbo.
3. JPMorgan Chase & Co. paid $920m+ related to schemes to defraud precious metals and treasury markets.
Regarding this takeaway, it has been stated here that the ability to prove spoofing in the commodities markets is easier because there are rules regarding spoofing that don't exist for stocks. Can you address the difference?
No trial compares those who participate in a trial to screened but not selected patients. Is this a new just invented metric?
I've been cleared to post this DM as written. If you knew who it was...He's never been wrong. Believe him or don't. $nwbo pic.twitter.com/vb0QJ8Jy5o
— annie post (@apwriter) February 27, 2023
The Wall Street Journal is reporting that the recent omnibus bill contains language that will prohibit doctors from prescribing treatments and medications off label.
https://www.wsj.com/articles/the-fda-wants-to-interfere-in-the-practice-of-medicine-physicians-patients-medical-devices-treatment-11673562165?st=uwa1nptotempl1t
If they hadn't bothered to get a top tier journal review the shorts would have had a field day saying the trial didn't succeed. You know how it works. The journal article was necessary and critical to the process of getting the drug to the finish line.
A Final Rejection Is Not the End
A final rejection from the USPTO sounds like the end of your patent application. However, fortunately, you still have opportunities to make the necessary amendments in your patent application. The word “final” in “final rejection” is actually a misnomer since a final rejection does not prevent you from prosecuting your patent application.
In fact, you have several procedural options at your disposal after having issued a final rejection.
Request for Continued Examination (RCE)
The first option is to submit a request for continued examination.
Along with the RCE, you must also submit a preliminary amendment.
An RCE reopens your application and the patent examiner takes another look at it.
The examiner reviews the application based on the amendments submitted in a preliminary amendment.
Filing an RCE can be costly.
For large entities, the USPTO charges a fee of $1,200 and $1,700 respectively for first and subsequent RCEs.
Small and micro entities get a discount of 50 percent and 75 percent respectively on the RCE fees.
Amendment After Final (AAF)
The second option is to submit an AAF. It does not involve any USPTO fees, but the examiner gets a limited time to review the application.
Thus, filing an AAF can be an effective strategy in cases where you can make straightforward amendments or arguments to overcome earlier rejections. It's especially helpful in rejections involving simple and minor issues like claim amendments to resolve rejections under 35 U.S.C. 112.
After Final Consideration Pilot (AFCP)
An AFCP is a relatively new option. You can file an AFCP, along with an AAF, to give more time to the examiner to consider your AAF. Note that the additional time the examiner gets is still limited.
To be eligible for an AFCP request, you must meet the following conditions:
You must be issued a final rejection.
You must have filed an AAF.
Your AAF must make an amendment to at least one independent claim, without having the effect of broadening the amended claim in any manner.
You must agree on a telephone interview, if required, with the examiner. Examiners do not always hold these interviews, but if held, they can be helpful in understanding the issues and examiners' point of view.
That's a District judge's decision I believe. It will no doubt be appealed.
Sounds like a good reason to call DI for clarification.
Haiku is one of her super Powers.
Kelly Grammer?
The AF article is already written. It will be published 5 seconds after the presentation
Could this be an adjunct treatment for dcvax? The trial results reported three instances of edema.
https://medicalxpress.com/news/2023-02-blood-pressure-drug-immunotherapy-induced-brain.html
You're supposing there are nwbo backers who would be buying as the price decreased so as to pick up shares as the price decreased so as to obtain enough shares to prevent further price depreciation to zero? Am I reading that right? Certainly nwbo can't do it alone because they don't have the capital.
If that's what happens you're suggesting the mms plan would fail because there won't be shares available to short at some point? But you also suggest that shares can be created to short even if there are none available. Naked shorting as it were. Given that, why wouldn't they just take the price to zero and bankrupt the company. Shorts walk away free without having to return shares and the naked shorts don't exist anymore.
I confess, reading your post has left me with a headache since I'm pretty sure I don't fully understand what you're getting at. The only thing I'm sure of from reading all that is that retail suffers no matter what happens.
If you read the article carefully they're talking about three different treatments at different places. The one you refer to isn't the study that references dcvax. The study on dcvax is the last one in the article
Automated manufacturing of dcvax is the long pole in the tent and that would have been true at CRL as well. The Sawston facility approval process seems to be moving along as expected.
Great post. Two quick comments. Laws and regulations aren't worth the paper they're printed on if they're not enforced. Washington is corrupt, bought by special interests and their focus is entirely on pleasing those who have bought them. You will have to look much deeper to find a solution to the current problems than just writing new laws and regulations.
Your comment about the wars we've fought brings to mind a comment and a warning from two previous presidents. Eisenhower famously warned about the military industrial complex and his warning was prescient. Our wars no longer serve the interests of the American people but instead the arms manufacturers and their enablers. The comment is by Calvin Coolidge I believe. When asked what America's business was he replied in a lengthier quote that has been shortened that the business of America is business. That's changed. The business of America now is war.
Stock buybacks are a fantasy of uninformed investors. A waste of capital for new, growing companies who need cash flow to grow the business. Buybacks are done primarily to increase share price to benefit mgt.
It's the lawyers job to get in touch with other companies, not nwbo.